Medicare Add-On Payments For CAR-T Should Reflect 80% Of Actual Costs, CMS Told
Biopharma firms and providers argue that CMS's current approach to awarding Medicare new technology add-on payments for CAR-T treatment is not suited to the high-cost therapy and is leading some hospitals to mark up billed charges substantially so they can get as much supplemental reimbursement as possible.
You may also be interested in...
Giving cell therapies as outpatient rather than inpatient treatments could be a way around the need for bundled payments, but it’s not universally applicable.
India has taken strides towards creating a supportive environment for its nascent gene therapy research, but the R&D and regulatory infrastructure is still evolving amid concerns over potential product costs.
A faculty member at the Indian Institute of Technology and the founder of Indian venture ImmunoACT hopes to deliver an indigenously developed CAR-T therapy at a fraction of current treatment costs.